title: Evaluation of the efficacy of heparins of varying molecular mass and duration of their use in the treatment of patients with acute venous thrombosis.
abstract: This paper analyses the results of examination and treatment of 90 patients with acute thrombosis in the inferior vena cava system. To verify the diagnosis, use was made of contrast phlebography (retrograde iliocavography), ultrasound angioscanning, and perfusion scanning of the lungs, The treatment was carried out using heparins of varying molecular mass given for a short and longer time together with indirect anticoagulants. It has been demonstrated that the use of low-molecular heparin does not produce any noticeable changes in the hemostatic system, which can be revealed by standard coagulation tests. In the authors opinion, a differentiated approach is required to the choice of the regimes of heparin therapy. The indications for the use of heparins have been worked out. Early administration of vitamin K raises the efficacy of anticoagulant therapy and shortens the time of heparin therapy. The use of low-molecular heparin allows to minimize the incidence of thromboembolic and hemorrhagic events without an increase in the total expenses for treatment.
authors.affiliation: Faculty of Surgery, Russian State Medical University, Moscow, Russia.
authors.forename: A I
authors.initials: AI
authors.lastname: Kirienko
authors.forename: S G
authors.initials: SG
authors.lastname: Leont'ev
authors.forename: E B
authors.initials: EB
authors.lastname: Petukhov
authors.forename: B V
authors.initials: BV
authors.lastname: Andreiashkin
authors.forename: I S
authors.initials: IS
authors.lastname: Lebedev
authors.forename: V P
authors.initials: VP
authors.lastname: Komarova
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D005268:Femoral Vein / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011152:Popliteal Vein / Q000503:physiopathology; D013997:Time Factors; D014682:Vena Cava, Inferior / Q000503:physiopathology; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D005343:Fibrinolytic Agents; D006493:Heparin